4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
06 2월 2024 - 6:05AM
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading
clinical-stage genetic medicines company focused on unlocking the
full potential of genetic medicines to treat large market diseases,
announced today that it has commenced an underwritten public
offering of $250.0 million of shares of its common stock. 4D
Molecular Therapeutics also intends to grant the underwriters a
30-day option to purchase up to an additional $37.5 million of
shares of common stock offered in the proposed offering. All of the
shares in the proposed offering are to be sold by 4D Molecular
Therapeutics. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Goldman Sachs & Co. LLC, BofA Securities, Jefferies and
Barclays are acting as joint book-running managers for the proposed
offering.
A registration statement relating to the shares to be sold in
the proposed offering has been filed with the U.S. Securities and
Exchange Commission (SEC) and became automatically effective upon
filing on February 5, 2024. Copies of the registration statement
can be accessed through the SEC’s website at www.sec.gov. The
offering will be made only by means of a prospectus. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the proposed offering may be obtained, when available,
from: Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, New York 10282, by telephone
at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com;
BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte,
North Carolina 28255-0001, Attention: Prospectus Department, or by
email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, New
York, New York 10022, by telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com; Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, by telephone at (888) 603-5847 or by email at
Barclaysprospectus@broadridge.com; or by accessing the SEC’s
website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About 4DMT4DMT is a leading clinical-stage
genetic medicines company focused on unlocking the full potential
of genetic medicines to treat large market diseases in
ophthalmology and pulmonology. 4DMT’s proprietary invention
platform, Therapeutic Vector Evolution, combines the power of the
Nobel Prize-winning technology, directed evolution, with
approximately one billion synthetic AAV capsid-derived sequences to
invent customized and evolved vectors for use in our wholly owned
and partnered product candidates. Our product design, development,
and manufacturing engine helps us efficiently create and advance
our diverse product pipeline with the goal of revolutionizing
medicine with potential curative therapies for millions of
patients. Currently, 4DMT is advancing five clinical-stage and two
preclinical product candidates, each tailored to address rare and
large market diseases in ophthalmology, pulmonology, and
cardiology. In addition, 4DMT is also advancing programs in CNS
through a gene editing partnership. 4D Molecular Therapeutics™,
4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are
trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the FDA
or any other regulatory authority. No representation is made as to
the safety or effectiveness of our product candidates for the
therapeutic uses for which they are being studied.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. All statements other than statements of historical
facts contained in this press release are forward-looking
statements, including statements regarding the proposed offering
and the grant to the underwriters of the option to purchase
additional shares. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, risks and
uncertainties related to market conditions and the completion of
the proposed offering on the anticipated terms or at all, and other
risks are described in greater detail under the section titled
“Risk Factors” contained in the prospectus supplement related to
the public offering and 4D Molecular Therapeutics’ current and
future reports filed with the SEC, including its most recent
Quarterly Report on Form 10-Q filed on November 9, 2023. Any
forward-looking statements that the company makes in this press
release are made pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, and speak only as of the date of
this press release. Except as required by law, the company
undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
Media: Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors: Julian PeiHead of Investor Relations
and Corporate
CommunicationsInvestor.Relations@4DMT.com267-644-5097
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024